Wolfgang Miesbach: Base Editing and the Future of Sickle Cell Disease Therapy
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on LinkedIn:
“Base editing. Gene editing 2.0?
At EHA 2026, Maria Morelló Miravet (Karolinska Institutet, Stockholm) showed how precise base editing of hematopoietic stem cells (HSCs) can move from concept to clinic in sickle cell disease (SCD):
Unlike classical CRISPR‑Cas9 nucleases that rely on double‑strand breaks and stochastic indels, base editors convert single nucleotides at predefined sites using deaminases fused to a Cas9 nickase.
This enables highly controlled editing of regulatory elements such as HBG promoters or BCL11A‑related loci, with the goal of re‑inducing fetal hemoglobin (HbF) while limiting chromosomal rearrangements and p53‑mediated stress responses.
This presentation is a powerful reminder that academia can drive first‑in‑class, highly sophisticated innovative programs, from basic biology and manufacturing to regulatory strategy and clinical implementation ”
Other posts featuring Wolfgang Miesbach on Hemostasis Today.
-
Aug 10, 2026, 10:47Sadia Kamal: Making Connections and Sharing Science at Hemostasis GRC
-
Aug 10, 2026, 10:34Ifeanyichukwu Ifechidere: TTP and ADAMTS-13 – The Enzyme Deficiency That Can Kill in 24 Hours
-
Aug 10, 2026, 10:30Mansi Kala: Key Takeaways from NHU 2026 in Haemostasis and Laboratory Practice
-
Aug 10, 2026, 08:41Gut Microbiota and Platelet Recovery After Radiation – Platelets Journal
-
Aug 10, 2026, 06:06Mostafa Faisal: What Does High Ferritin Really Mean
-
Aug 10, 2026, 05:45Colin Holburn: Key Laboratory Clues to End Organ Damage
-
Aug 10, 2026, 05:35George Dimitrov: SII and Cancer – What Can This Marker Really Tell Us
-
Aug 10, 2026, 05:01New Clinical Evidence on Emicizumab and Breastfeeding – JTH
-
Aug 10, 2026, 04:53Abdulaziz Elnusiry: Pulmonary Embolism – The Silent Emergency We Need to Talk About